Meet our 2023 HBA Luminary award winner honored for inspiring others
Meet our 2023 HBA Luminary award winner honored for inspiring others
Search
Growing fresh produce for a cause at our U.S. headquarters
Growing fresh produce for a cause at our U.S. headquarters
Fighting Non-Communicable Diseases | Boehringer Ingelheim US
Read more on Boehringer Ingelheim's new NCD initiative, aiming to reduce NCD prevalence and capture the impact of our product portfolio for our patients.
Biberach
Click here to view our Biberach site, in Southern Germany, home to the largest research & development center within Boehringer Ingelheim’s global network.
Lyon
The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.
Partnering in CardioMetabolic Diseases
Partnering in CardioMetabolic Diseases
Sunshine Act Compliance
Sunshine Act Compliance
Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer
Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer
Low-WAC interchangeable biosimilar is now available
Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.
Identifying Risk Factors to Improve Outcomes in Chronic Kidney Disease
Identifying Risk Factors to Improve Outcomes in Chronic Kidney Disease
Employees compassionately help local communities with country-wide food drive
Coming together to bring food to people in need
Shanghai
Shanghai serves as an important hub for all of the company’s three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.
Our partners Bioveta
Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
Full data announced in DINAMO trial in young people with T2D
Jardiance (empagliflozin) tablets is the first SGLT2 inhibitor to show statistically significant
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
A Moment To Reflect on the Evolving Approach for Diabetes Management | Boehringer Ingelheim US
A Moment To Reflect on the Evolving Approach for Diabetes Management
Targeting HER2 in cancer
Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.
Taking patient centricity to new heights
Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.
Niha Agarwalla
My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
Boehringer Ingelheim Partners with Express Scripts on their Patient Assurance Program Expansion for People with Type 2 Diabetes
Boehringer Ingelheim Partners with Express Scripts on their Patient Assurance Program Expansion for People with Type 2 Diabetes
Social Impact | COVID-19 | Boehringer Ingelheim US
Click to find out more on how Boehringer Ingelheim (BI) is standing together with our communities to support the fight against the COVID-19 pandemic.
Nintedanib Study: Systemic Sclerosis & Lung Fibrosis | Boehringer Ingelheim US
Boehringer Ingelheim today announced that the first patient was enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in SystemicSClerosIS) study.
Boehringer Ingelheim, Sodexo and Food Rescue US Collaborate to Nourish Fairfield County’s Food Insecure in Response to the COVID-19 Crisis
Boehringer Ingelheim, Sodexo and Food Rescue US Collaborate to Nourish Fairfield County’s Food Insecure in Response to the COVID-19 Crisis
How Boehringer Ingelheim US Helps Injured Veterans | Boehringer Ingelheim US
Read more on how Boehringer Ingelheim supports injured veterans in making a fresh start through the use of service dogs, with the Warrior Canine Connection.
Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease